🌱 KidneyEnergy.com

← all stories

Peer reviewed Reversal pharmaceutical checked against the paper

two White men in their sixties with relapsed acute myeloid leukemia

minimal change disease (nephrotic syndrome) as the first sign of AML relapse after a stem cell transplant

Beforenephrotic-range protein in the urine and acute kidney injury after the transplant; one patient needed dialysis
Afterkidney function improved only after leukemia treatment started; one patient came off dialysis

Both men had a kidney biopsy that confirmed minimal change disease. Steroids did not stop their kidneys from getting worse. Their kidney function only got better after doctors started treatment aimed at the leukemia itself, not more immune-suppressing drugs. One of the two men recovered enough to stop dialysis. The report says the key was controlling the underlying cancer.

In two men whose leukemia came back after a stem cell transplant, sudden kidney damage was a first warning sign, and their kidneys only recovered once the leukemia itself was treated.

Key takeaways

Why it might work

The paper frames the kidney damage as a paraneoplastic problem, which means the kidneys were being harmed as a side effect of the returning leukemia rather than by a separate kidney disease. Because the leukemia was the real driver, adding more immune-suppressing steroids did not help. Getting the cancer back under control removed the source of the harm, and that is why kidney function started to recover only after leukemia-directed treatment began.

The honest limits

Questions to bring your nephrologist

Researchers: Saleem K · Kamat S · Khurram NA · Hendawy BS · Ito S · Amarapurkar P

PubMed ↗added 2026-08-15